TerrAscend Corp.

TSX:TSND.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.52 -1.61%

-$0.02 today

Market cap
$193.65M
Beta
2.04
P/E (TTM)
-2.5
EPS (TTM)
-$0.26
52W Low $0.33High $2.00

Volume 0.26M

Average 0.31M

TSND.TO Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

TerrAscend Corp.TSX: TSND.TO

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue declines year over year

Q1 FY2026 revenue of $64.46M fell 9.2% year over year, in line with the -8.7% change in trailing-twelve-month revenue. Sequentially, it fell 4.0% from the prior quarter. Over 3 fiscal years it compounded at +3.3% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 3 analysts of $270.83M (+2.2%) for the fiscal year ending Dec 2026, a step up from the -13.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$64.46M-4.0% QoQ
Last fiscal yearDec 2025
$265.12M-13.6% YoY
LTMMar 2026
$261.74M-8.7% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.2%+1.9%+11.1 pp
1 year-13.6%+2.2%+15.7 pp
3-year CAGR+3.3%+6.5%+3.2 pp
5-year CAGR+6.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
265.12M USD
Year-over-year change
-13.6%
4-year CAGR
+2.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How TSND.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -8.7% is the lowest of 9, against a peer median of +18.9%.
  • Over three fiscal years its annual growth of +3.3% compares with a peer median of +11.2%.
TSND.TO Competitors
Revenue for TSND.TO and competitors
Company Period LTM YoY 3-year CAGR
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$318.43M CAD-7.2%+11.2%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$310.92M CAD+15.6%-5.1%
DR.TOMedical Facilities CorporationLTM Mar 2026$305.39M USD+0.1%-15.2%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$274.19M CAD+41.3%—
TSND.TOTerrAscend Corp.LTM Mar 2026$261.74M USD-8.7%+3.3%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$158.57M CAD+22.2%+17.0%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$55.76M USD-1.8%-2.8%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$51.17M USD+65.5%+207.5%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$50.92M USD+28.9%+35.4%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$0 USD——
Peer median (excluding TSND.TO) —+18.9%+11.2%

Competitors are the stored peer set for TSND.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue243.36M240.45M317.33M306.68M265.12M
Cost of Revenue109.32M203.35M112.49M156.72M131.93M
Gross Profit134.04M119.74M138.02M149.96M133.19M
Gross Margin55.1%49.8%43.5%48.9%50.2%
Research & Development00000
Selling, General & Admin73.71M116.64M112.17M111.33M82.41M
Operating Expenses94.12M150.69M179.56M167.07M87.78M
Depreciation & Amortization13.63M24.6M22.7M22.99M17.51M
EBITDA44.96M(246.52M)(1.03M)6.16M62.92M
EBITDA Margin18.5%-102.5%-0.3%2.0%23.7%
Operating Income31.33M(23.04M)(19.87M)(17.11M)45.41M
Operating Margin12.9%-9.6%-6.3%-5.6%17.1%
Interest Income00000
Interest Expense24.57M37.9M35.11M35.4M36.93M
Other Income / Expenses12.46M(277.92M)(38.97M)(35.13M)(40.34M)
Income Before Tax43.78M(300.95M)(58.83M)(52.23M)5.06M
Pre-Tax Margin18.0%-125.2%-18.5%-17.0%1.9%
Income Tax Expense28.88M(10.46M)23.45M20.44M29.98M
Net Income3.06M(303.96M)(91.1M)(80.23M)(87.74M)
Net Margin1.3%-126.4%-28.7%-26.2%-33.1%
EPS (Basic)0.07(1.31)(0.32)(0.28)(0.29)
EPS (Diluted)0.01(1.31)(0.32)(0.28)(0.29)
Weighted Avg Shares181.06M244.35M279.29M291.51M301.08M
Weighted Avg Shares (Diluted)208.71M244.35M279.29M291.51M301.08M

TerrAscend Corp.

TSX:TSND.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.